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Edited by Lev KisselevAbstract The HIV-1 Rev protein plays a key role in virus rep-
lication by allowing export to the cytoplasm of unspliced or sin-
gly-spliced RNAs. In this report, we investigated whether Rev is
modiﬁed by ubiquitination or sumoylation. Whereas no evidence
of sumoylation was obtained, transient expression experiments
showed that ubiquitin conjugates to Rev as high molecular weight
polyubiquitin chains. Mutation of the three lysine residues of Rev
showed that the site of ubiquitin conjugation is Lys-115. Experi-
ments with ubiquitin mutants including a single lysine at every
seven possible position indicated that branching of the polyubiqu-
itin chains mainly involves Lys-33. Mutation of Rev Lys-115 to
arginine reduces markedly the steady state amount of the pro-
tein, but does not impair its ability to export RNA via the Rev
response element. These observations support the notion that
polyubiquitination of Rev stabilizes the viral protein but hinders
its activity.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Post-translational modiﬁcations potentially aﬀect impor-
tantly the activity and fate of cellular as well as viral proteins.
Among these modiﬁcations, ubiquitination is receiving an ever
increasing attention and it appears that it can modify the activ-
ity of the substrate protein in multiple ways [1]. Ubiquitin can
be covalently linked to lysine side chain as a single monomer or
as polyubiquitin chains of which internal branching residue can
vary. The most common is Lys-48, thereby creating a signal for
protein degradation by the proteasome, but other lysine resi-
dues, as Lys-63 and Lys-6, are emerging as alternative branch-
ing possibilities and it is likely that additional options exist in
mammalian cells [2–5]. Depending on these parameters, the
eﬀect of ubiquitin addition can be activatory, inhibitory or
can lead to active degradation of the protein by the proteasome
[2]. These diﬀerent outcomes are likely related to diﬀerent con-
formations of the ubiquitin polymers [6]. In the case of HIV-1,
it has been shown that polyubiquitination of Tat by Hdm2 does
not destabilize the transactivator and increases its activity [7].
Besides Tat, an important protein for replication of the virus*Corresponding author. Fax: +33 472728080.
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doi:10.1016/j.febslet.2006.10.015is Rev which permits translation of the late Gag, Pol and Env
proteins by allowing export to the cytoplasm of the non-spliced
or intermediary spliced viral messenger RNAs [8]. Rev shuttles
between the nucleus and cytoplasm and acts by interacting with
the viral RNA through the Rev response element (RRE), as
well as by establishing various protein-protein interactions,
importantly with the exportin CRM1 [9–12], but also with
other proteins as nucleoporins, RNA helicases or a kinesin-like
[13–19]. As we observed that overexpression of ubiquitin by
transient expression aﬀects the level of Rev present within cells,
we investigated whether this key factor of HIV-1 replication
could be modiﬁed by ubiquitination and how it would aﬀect
its properties.2. Materials and methods
2.1. Constructs
Plasmid pSG-His6Rev was constructed by amplifying the Rev cod-
ing sequence with the following sense and antisense primers:
5 0-TCGGAATTCCACCATGGTTCATCATCACCATCACCATGG-
TGGAGGCGCAGGAAGAAGCGGAGAC-3 0, 5 0-TTAATAAGA-
TCTTAACAGCACTATTCTTTAGTTCC-3 0. The ampliﬁed fragment
was digested by EcoRI and BglII restriction enzymes and inserted be-
tween the EcoRI and BamHI restriction sites of the pSG5 expression
vector. pSG-FLAG-Rev was generated by inserting the Rev coding se-
quence in plasmid pSGF which is a derivative of pSG5 which includes a
FLAG epitope [20]. The Rev protein from HIV-1 LAI includes three
lysine residues at positions 14, 20 and 115. Using the Transformer
Site-DirectedMutagenesis Kit (Clontech) and appropriate oligonucleo-
tides, along with pSG-His6Rev vector, each of these lysines were
mutated to arginine, alone or in combination giving vectors pSG-His6-
RevK14R, pSG-His6RevK20R, pSG-His6RevK115R, pSG-His6-
RevK14-20R, pSG-His6RevK14-115R, pSG-His6RevK20-115R and
pSG-His6RevK14-20-115R. Each construct was veriﬁed by DNA
sequencing. Plasmids expressing ubiquitin mutants were generated as
follows: The sequence coding for HA-tagged ubiquitinWT or including
a single lysine residue at position 48 or 63, were excised from plasmids
kindly provided by Dr. V. Dixit [21] by HindIII–BamHI digestion and
inserted between the HindIII–BglII restriction sites of the pTL1 vector,
giving plasmids pTL1-HAUbWT, pTL1-HAUbK48 and pTL1-
HAUbK63, respectively. pTL1-HAUbK6 was generated by amplifying
the HAUb sequence from pTL1-HAUbK63 with the following sense
and antisense primers: 5 0-CGGCCGGATCCCAGATCTTCGT-
GAAAACCC-3 0, 5 0-GAGCTCTCGAGCTCAGCCTCCCCGCAGT-
CTCAGGACCAGGTGCAGGGTGCTCTCTCTCTGG-3 0. The am-
pliﬁed fragment was digested with BglII and SacI and inserted between
the BglII and SacI restriction sites of pTL1-HAUbK48. pTL1-
HAUbK0 was generated by amplifying the HAUb coding sequence of
pTL1-HAUbK6 with the following sense and antisense primers: 5 0-
GATCCCAGATCTTC- GTGAGAACCC-3 0, 5 0-GCGCAGCGAGT-
CAGTGAGCGAGG-3 0. The ampliﬁed fragment digested by BglII
and SacI was inserted between BglII and SacI of pTL1-HAUbK48.
Vectors pTL1-HAUbK11, pTL1-HAUbK27, pTL1-HAUbK29 andblished by Elsevier B.V. All rights reserved.
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Mutagenesis Kit (Clontech) and appropriate oligonucleotides, along
with the pTL1-HAUbK0 vector. Each construct was veriﬁed by DNA
sequencing.2.2. Cell culture and transfection
COS7 and 293T cells were cultured in DMEM plus 5% FCS and
antibiotics at 37 C in a 10% CO2-humidiﬁed atmosphere. Cells were
transfected by the calcium phosphate co-precipitation procedure as
previously described. The amount of SV40 early promoter containing
plasmid was adjusted to a constant level with pSG5.2.3. Immunoprecipitation and immunoblot
Cells were lysed in RIPA buﬀer (50 mM Tris–HCl, pH 8.0, 150 mM
NaCl, 1% NP40, 0.1% SDS, 0.5% deoxycholate) complemented with
10 mM iodoacetamide to preclude deubiquitination. Immunoprecipi-
tation of FLAG-tagged Rev proteins was performed using the M2
monoclonal antibody to FLAG (Sigma) diluted 1/250. After incuba-
tion for 2 h at 4 C protein–antibody complexes were captured on pro-
tein-A-Sepharose beads (Sigma) by mixing for 45 min at 4 C. Beads
were collected by centrifugation and washed three times in lysis buﬀer.
After elution by incubation of beads for 10 min at 80 C in protein gel
loading buﬀer, immunoprecipitated proteins were separated by SDS–
PAGE.
Immunoblots were performed by electro-transferring the proteins
to PVDF membranes (Amersham Biosciences). Then appropriate
total protein amounts were measured using the Dc assay (Biorad)
to analyse equal quantities of each extract. Primary antibodies used
for detection were either a monoclonal antibody directed against
Rev [22] diluted 1/5000, a monoclonal antibody to b-actin (Sigma)
diluted 1/5000, a monoclonal antibody to the HA epitope (Roche)
diluted 1/500, the M2 monoclonal antibody to FLAG (Sigma) diluted
1/1000, or a polyclonal antibody to ribonucleotide reductase poly-
peptide M2 (RRM2) diluted 1/1000. Secondary antibodies coupled
to peroxydase directed against either mouse or rabbit Ig (Amersham
Biosciences) were used diluted 1/10000. Revelation was performed by
chemiluminescence using the ECL plus reagent (Amersham
Biosciences).2.4. Ni-NTA pull down
Cells were lysed in buﬀer A (6 M guanidinium–HCl, 0.1 M Na2H-
PO4/NaH2PO4, 0.01 M Tris–HCl, pH 8.0, 5 mM imidazole, 10 mM
b-mercaptoethanol). The extracts were incubated with Ni2+ nitrilotri-
acetic acid (NTA) beads for 2.5 h at room temperature and the beads
were washed with buﬀers A, B (8 M urea, 0.1 M Na2HPO4/NaH2PO4,
0.01 M Tris–HCl, pH 8.0, 10 mM imidazole, 10 mM b-mercaptoetha-
nol) and C (8 M urea, 0.1 M Na2HPO4/NaH2PO4, 0.01 M Tris–HCl,
pH 6.3, 10 mM imidazole, 10 mM b-mercaptoethanol). Bound pro-
teins were eluted with buﬀer D (300 mM imidazole, 0.15 M Tris–
HCl, pH 6.7, 30% glycerol, 0.72 M b-mercaptoethanol, 5% SDS).Fig. 1. Ubiquitin intracellular level aﬀects stability of Rev which is
modiﬁed by addition of polyubiquitin chains. (A) COS7 cells cultured
in 6 well plates were transfected with 0.5 lg of pSG-His6Rev together
without (lane 1) or with 25, 50, 125 and 250 ng of pTL1-HAUb (lanes
2, 3, 4 and 5). Forty-two hour after transfection cells were lysed in
RIPA buﬀer and equal total protein amounts were migrated through a
12% polyacrylamide–SDS protein gel. Immunoblot was performed
using either the antibody to Rev (upper panel) or to b-actin (lower
panel) as control. Numbers (corresponding to kDa) on the left indicate
positions of bands of a molecular weight marker run in parallel. (B)
293T cells cultured in 10-cm-diameter plates were transfected with 4 lg
of pSG-FLAG-Rev together without (lane 1) or with 0.5 (lane 3) and
1 lg (lanes 2 and 4) of pTL1-HAUb. For lanes 3 and 4, 20 lM of the
proteasome inhibitor MG132 were added to the culture medium 5 h2.5. Cell fractionation
Cells were washed twice with ice cold PBS and collected by centrifu-
gation. Pellets were resuspended in buﬀer containing 10 mM HEPES,
pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT and 0.5 mM
PMSF and incubated at 4 C for 30 min. Cell breakage was performed
with a Dounce (B-pestle). After centrifugation at 2500 rpm, 4 C, for
10 min, the pellet was resuspended in buﬀer containing 20 mM
HEPES, pH 7.9, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2,
0.2 mM EDTA, 10 lM ZnCl2, 0.5 mM DTT and 0.5 mM PMSF, then
centrifuged at 9000 rpm, 4 C, for 30 min to clear the nuclear fraction
from debris. The supernatant of the ﬁrst centrifugation was ultracen-
trifuged at 40000 rpm, 4 C, for 30 min to separate the cytoplasmic
fraction (supernatant) from membranes (pellet resuspended in TE
10:1).before harvest of the cells. Immunoprecipitation were performed using
equal total protein amounts with the antibody to FLAG and
immunoprecipitated proteins were analysed by immunoblot using the
antibody to HA (upper panel) or to FLAG (lower panel). The
positions of FLAG-Rev and of the smear corresponding to poly-
ubiquitin chains are indicated on the right.2.6. CAT assay
CAT protein amounts in transfected cells were measured with equal
total protein amounts of cell extract by using an ELISA assay (Roche)
according to the manufacturer’s instructions.3. Results
3.1. Rev is modiﬁed by polyubiquitination
When cells were transfected with increasing amounts of a
vector expressing wild type ubiquitin tagged at its N-terminus
by a HA epitope, the smear of polyubiquinated proteins grad-
ually increased (not illustrated). Under these conditions co-
transfection of a constant amount of a vector encoding Rev
and immunoblot analysis showed that the intracellular concen-
tration of viral protein increases (Fig. 1A). At high levels of
ubiquitin overexpression this eﬀect was attenuated (Fig. 1A,
lane 5). As the amount of SV40 early promoter containing
expression vector was adjusted to a constant level for each
point, this variation was likely not related to Rev expression
variation. This observation could be interpreted as a stabilizing
eﬀect of ubiquitination of Rev resulting in an apparent in-
crease in the non-modiﬁed form of the protein, as a hardly
controllable deubiquitination occurs during preparation of
the extract. Hence it was examined whether Rev was directly
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co-immunoprecipitation experiments. Cells were transfected
with a vector expressing Rev tagged with the FLAG epitope
at its N-terminus, together with the plasmid expressing HA-
ubiquitin. Immunoprecipitation was performed using the anti-
body to FLAG and precipitated proteins were analyzed by
immunoblot with the antibody directed against the HA epi-
tope. This revealed a smear of bands of high molecular
weights, which were likely to correspond to the polyubiquiti-
nated forms of Rev (Fig. 1B, lane 2). These bands were not ob-
served when immunoprecipitation was performed using cells
transfected solely with the HA-ubiquitin expression vector
(data not shown). Interestingly, the intensity of this smear
was not increased when cells were treated with the proteasome
inhibitor MG132 (Fig. 1B, compare lanes 2 and 4), by contrast
with what can be observed for many polyubiquitinated pro-
teins (not illustrated). As these immunoprecipitations were car-
ried out in the stringent RIPA buﬀer, and also as the high
molecular weight bands were not increased by proteasome
inhibition, these results suggested that Rev is modiﬁed by poly-
ubiquitination, this event having the particularity of stabilizing
the protein rather than leading to its degradation.Fig. 2. Lysine 115 of Rev is required for ubiquitin conjugation. (A)
Schematic representation of the lysine to arginine Rev mutants. (B)
293T cells cultured in 10-cm-diameter plates were transfected with 2 lg
of plasmid encoding H6-Rev wild-type (lanes 1 and 2), or mutated
(lanes 3–9), without (lane 1) or with (lanes 2–9) 0.2 lg pTL1-HAUb.
Forty-two hour after transfection, Ni-NTA Pull down were performed
and analysed by immunoblot using either the antibody to Rev (lower
panel) or the antibody to HA (upper panel). Numbers on the left (kDa)
indicate position of bands of a molecular weight marker.3.2. Lys-115 is the site of modiﬁcation in Rev
The Rev coding sequence which was used for these experi-
ments was from the HIV-LAI isolate and includes three lysine
residues at positions 14, 20 and 115. A series of mutants was
constructed with each possible combination of mutation of a ly-
sine to an arginine for one, two and three residues (Fig. 2A).
This was done with Rev tagged at its N-terminus with a six his-
tidine motif (H6-Rev). These constructs were transfected with
the vector expressing HA-ubiquitin. Cells were lysed under
strongly denaturating conditions (see legend to Fig. 2B) and
the Rev protein was puriﬁed using a Ni-NTA column. Analysis
of Rev proteins eluted from the column by immunoblot with
the antibody to HA showed a smear of high molecular weight
bands corresponding to polyubiquitinated Rev (Fig. 2B, lane
2). Mutation of either Lys-14 or Lys-20 did not aﬀect intensity
of this smear (Fig. 2B, lanes 3 and 4). By contrast, mutation of
Lys-115 markedly reduced it (Fig. 2B, lane 5). Mutation of both
Lys-14 and Lys-20 did not lead to disappearance of the smear
(Fig. 2B, lane 6), whereas it was reduced when the K115R
mutation was combined with K14R or K20R mutations or
both together (Fig. 2B, lanes 7–9). As under these strongly
denaturing conditions it is very unlikely that the smear corre-
sponds to associated proteins, these observations conﬁrmed
that Rev is modiﬁed by polyubiquitination. They also establish
that Lys-115, the penultimate amino acid residue of the protein,
is the site of ubiquitination.3.3. Lys-33 of ubiquitin is the most eﬃcient residue for branching
of ubiquitin chains added to Rev
In polyubiquitin chains, linkage of the various monomers
can occur through diﬀerent lysine residues. In order to evaluate
how branching occurs in the case of Rev, mutants of ubiquitin
which include a single lysine at the diﬀerent positions were gen-
erated (Fig. 3A). Cells were transfected with vectors expressing
these HA-tagged ubiquitin mutants together with the plasmid
producing H6-Rev. The polyubiquitinated forms of the viral
protein were analyzed by immunoblot after puriﬁcation under
strongly denaturing conditions, as described before for resultsof Fig. 2. With the HAUb-K0 mutant, in which all lysine res-
idues were mutated to arginine, no high molecular weight
derivatives of Rev were observed (Fig. 3B, lane 8, upper
panel). By comparing the intensity of the smear, and also its
progression towards high molecular weight forms, the mutant
which appears the most eﬃcient is HAUb-K33, which includes
a single lysine at position 33 (Fig. 3B, lane 5, upper panel). A
smear was also clearly observed with HAUb-K27, but it faded
in the high molecular weights (Fig. 3B, lane 3). HAUb-K63
was also able to generate polyubiquitinated forms of Rev
(Fig. 3B, lane 7, upper panel), but the intensity of the smear
was weaker as compared with that resulting from HAUb-
K33, especially by considering that the amount of H6-Rev
was higher for this point in this experiment (Fig. 3B, lanes 5
Fig. 3. Branching of the ubiquitin chains added to Rev mainly
involves lysine 33. (A) Schematic representation of the lysine to
arginine ubiquitin mutants. (B) 293T cells cultured in 10-cm-diameter
plates were transfected with 2 lg of plasmid encoding H6-Rev wild-
type and 0.2 lg of each pTL1-HAUb derivatives expressing ubiquitin
without any lysine residue (K0, lane 8) or with a single lysine residue at
position 6, 11, 27, 29, 33, 48, 63 (K6, K11, K27, K29, K33, K48 and
K63, lanes 1, 2, 3, 4, 5, 6 and 7, respectively). Puriﬁcation and analysis
of the Rev-ubiquitin conjugates were performed as described in the
legend to Fig. 2. Upper panel corresponds to the immunoblot done
using the antibody to HA and lower panel to that with the antibody to
Rev. Numbers on the left (kDa) indicate position of bands of a
molecular weight marker.
Fig. 4. Mutation of Rev Lys-115 aﬀects its stability and intracellular
localisation. (A) 293T cells cultured in six well plates were transfected
with 0.5 lg pSG-His6Rev, either wild type (lane 1) or mutated as
indicated on the ﬁgure (lanes 2–8). Cells were lysed in RIPA buﬀer and
equal total protein amounts were analyzed by immunoblot with either
the antibody to Rev (upper panel) or with the antibody to b-actin
(lower panel). Numbers on the left (kDa) indicate position of bands of
a molecular weight marker. (B) 293T cells cultured in 6-cm-diameter
plate were transfected with 1 lg pSG-His6Rev either wild type (lanes
1–3) or including the K115R mutation (lanes 4–6). After cell
fractionation, total protein concentrations were measured, and 10 lg
of the cytoplasmic (c) and membrane (m) fractions, along with 5 lg of
the nuclear (n) fraction were analysed by immunoblot with either the
antibody to Rev (upper panel) or the antibody to RRM2 (lower panel),
which is a cytoplasmic protein and used here as a control of the
fractionation process. The positions of H6-Rev and RRM2 are
indicated on the right.
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weak intensity, particularly for HAUb-K48 which is appar-
ently unable to cause modiﬁcation of Rev (Fig. 3B, lane 6,
upper panel). These observations support the notion that
branching of the polyubiquitin chains added to Rev occurs
mainly via lysine 33, or less eﬃciently via lysines 27 and 63.
In agreement with the fact that polyubiquitination of Rev does
not cause its degradation, this experiment showed that Lys-48
is not used as a branching residue for modiﬁcation of Rev.
3.4. Impairment of Rev polyubiquitination reduces its
abundance, but does not weaken its activity
Transfection of the vectors expressing the various Rev mu-
tants and immunoblot analysis of total protein extracts indi-
cated that the presence of the K115R mutation leads to a
reduced abundance of the protein (Fig. 4A, compare Rev signal
in lanes 1, 2, 3 and 5 with that in lanes 4, 6, 7 and 8). This is in
agreement with the previous observation showing an increase
in the Rev amount when polyubiquitination was stimulated
by ubiquitin overexpression. The intracellular distribution of
the Rev K115R mutant was also analyzed. In agreement with
the previous experiment, a reduced amount of the mutant
was observed in the cytoplasmic, nuclear and membrane frac-
tions, but it also appeared that the presence in the cytoplasmwas particularly aﬀected (Fig. 4B, compare Rev signal in lanes
1 and 4). This suggests that this Rev mutant is either destabi-
lized in the cytoplasm or imported within the nucleus more eﬃ-
ciently than the wild type. Finally, it was analyzed how
impairment of Rev ubiquitination by mutation of the Lys-115
aﬀects the activity of the protein. This was tested with the
pDM128 reporter construct that includes the CAT coding se-
quence and the RRE motif in an intron [23]. Rev is known to
markedly increase production of CAT from this construct. It
was ﬁrst checked that the activity detected was proportional
to Rev concentration in the range of expression vector amount
used for transfection (Fig. 5A). Under these conditions, muta-
tion of both Lys-14 and Lys-20 had no signiﬁcant eﬀect on this
activity (Fig. 5B). Expression of the K115R mutant caused a
limited increase in CAT production as compared to both the
wild type and the K14-20R mutant, but as already described
(Fig. 4A) the intracellular amount of the K115R mutant is
much lower as detected by immunoblot in whole cell extract
(data not shown). When the same experiment was performed
with expression vectors amounts adjusted to correct for the dif-
ference in intracellular concentration, a ﬁvefold stronger activ-
ity was observed for the K115R mutant as compared with the
wild type (data not shown). Collectively, these data indicate
that polyubiquitination of Rev on Lys-115 does not contribute
to its RNA export activity, but even has rather an inhibitory ef-
fect.
Fig. 5. Mutation of Rev Lys-115 increases its activity. (A) 293T cells in
six wells plate were transfected with 5, 15, 20, 25 and 125 ng of pSG-
His6Rev, together with 50 ng of the reporter plasmid pDM128 [23]
which includes the chloramphenicol acetyl transferase coding sequence
in an intron along with the RRE motif. Forty-two hour after
transfection, CAT protein amounts in extracts were measured and
results are represented as the fold activation relative to the value
obtained with the pDM128 plasmid alone. (B) Experiment was
performed as described for panel (A) by transfecting 50 ng of pSG-
His6Rev, either wild-type (WT), with the K14-20 R mutation or with
the K115R mutation. Each point of transfection was made in
triplicate. The graph represents the mean of fold activation obtained
for the three independent points of transfection and error bars
correspond to standard deviation.
Table 1
Sequences of Rev proteins from various HIV-1 isolates were obtained
from the HIV sequence database (http://www.hiv.lanl.gov/) and
sequences from the diﬀerent sub-types of the M group were aligned
using the Clustal W program (http://pbil.univ-lyon1.fr/)
Sub-type Number of
sequences
Number of
sequences with
K at 1
Percentage of
sequences with
K at 1 (%)
A 62 48 77.4
B 96 85 88.5
C 36 3 8.3
D 44 26 59.1
F 10 8 80
G 4 4 100
H 3 3 100
J 2 2 100
K 2 2 100
This table gives the number of sequences aligned for each sub-type, the
number of sequences with a lysine residue penultimate to the C-ter-
minus and the percentage of sequences which includes this occurrence.
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Our observations establish that Rev is modiﬁed by polyubiq-
uitination on its penultimate amino acid residue. Comparison
of the diﬀerent known sequences of Rev shows that lysine at
this position is well-conserved (Table 1) and therefore suggests
that this modiﬁcation is quite general for the Rev protein from
various HIV-1 subtypes. The experiments shown in this report
with ubiquitin have also been carried out with vectors express-ing SUMO-1, but conjugation of this small Ub-like protein to
Rev has not been observed. Therefore modiﬁcation on Lys-115
seems to occur only with ubiquitin. It also appears that the
polyubiquitinated forms of Rev migrate at high molecular
weight and no bands were observed at lower positions between
Rev and its modiﬁed derivatives, excluding addition of a single
or of few ubiquitin monomers. Paradoxically, addition of these
long polyubiquitin chains does not destabilize Rev, but rather
seems to be correlated with an increased total amount of the
viral protein. Interestingly our data show that branching of
these polyubiquitin chains occurs through a unconventional
lysine residue of ubiquitin: Lys-33. To our knowledge such a
branching has not been described in mammalian cells so far,
but this observation agrees with the proteomic study per-
formed in yeast which shows that every seven lysine residues
of ubiquitin are used for branching in vivo [24]. An interesting
point of future studies will be to identify the E3 ubiquitin ligase
generating this type of branching. Non-destabilizing addition
of ubiquitin has also been documented for the HIV-1 Tat
and HTLV-1 Tax proteins [7,25,26]. For Tat, ubiquitination
was found to have a positive eﬀect on the activity [7], but poly-
ubiquitination of Tax inhibited its ability to transactivate the
HTLV-1 LTR [26]. Similarly to this latter case, by considering
the ratio activity versus protein amount, polyubiquitination
has to be regarded as inhibitory for Rev. It is possible that
the polyubiquitin chains inhibit interaction with RNA and
partner proteins. This modiﬁcation could also inhibit reimport
of the protein within the nucleus, as suggested by the relative
increased presence of the Rev K115R mutant within the
nucleus. In conclusion, addition of polyubiquitin chains to
Rev at its C-terminus has the beneﬁt of increasing the intracel-
lular amount of the protein, but at the cost of a reduced
activity.
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